BioSpace News Archive

Azenta, Inc. will announce fiscal first quarter 2024 earnings which ended on December 31, 2023, on Wednesday, February 7, 2024, after the market closes.

Scientific Industries, Inc. announced the closing of an approximately $7.0 million private placement financing consisting of an aggregate of 3,500,000 shares of its common stock and accompanying warrants to purchase up to 4,535,000 shares of common stock at a combined effective offering price of $2.00 per unit.

BrightSpring Health Services, Inc. (“BrightSpring” or “BrightSpring Health Services”) today announced the pricing of an initial public offering of 53,333,334 shares of its common stock at $13.00 per share and a concurrent offering of 8,000,000 of its 6.75% tangible equity units (“Units”), with a stated amount of $50.00 per Unit.

ArriVent BioPharma, Inc. announced the pricing of its upsized initial public offering of 9,722,222 shares of its common stock at a public offering price of $18.00 per share.

Vanda Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses.

Bloom Burton & Co. (“Bloom Burton”) is excited to announce the launch of the 2024 Bloom Burton Award and to open nomination submissions.

PharmAla Biotech Holdings Inc. is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License by Health Canada, Canada’s federal health regulator.

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator.

The U.S. Food and Drug Administration has approved Dupixent® for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis.

Travere Therapeutics, Inc., announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.